AG真人官方

Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.

• Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
• Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company鈥檚 planned Token Generation Event.
• Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
• Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
• Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
• Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).

No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE鈥檚 common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June 鈥� 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE鈥檚 ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company鈥檚 underlying fundamentals.

Form 144 filing for NVIDIA Corporation (NVDA) dated 07/09/2025 discloses chief executive officer Jen-Hsun Huang鈥檚 intention to sell 75,000 common shares through Charles Schwab & Co. at an aggregate market value of $12.23 million. The filing follows an extended series of sales made during the previous three months in which Huang disposed of 825,000 shares for gross proceeds of approximately $127.54 million.

The shares to be sold were acquired via performance stock awards on 12/13/2023 (70,145 shares) and 03/20/2024 (4,855 shares), indicating they are part of routine equity compensation. The notice certifies that the filer is unaware of any undisclosed material adverse information and, if relying on a Rule 10b5-1 trading plan, such a plan was adopted prior to the sale instructions.

The filing references a share count outstanding of 24.4 billion (as listed in the form), implying the planned sale represents a mathematically negligible fraction of reported shares outstanding. Nevertheless, the continued pace and scale of insider selling鈥攐ver $127 million in three months鈥攎ay draw investor attention to potential diversification or liquidity motives by NVIDIA鈥檚 long-tenured CEO.

Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.

The prospectus reiterates Tectonic鈥檚 strategy of developing biologics that modulate GPCRs via its proprietary GEODe鈩� platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.

Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.

As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.

ACM Research, Inc. (Ticker: ACMR) 鈥� Form 144 filing

An individual named Lisa Yi Lu Feng has filed a notice to sell up to 15,000 common shares of ACM Research, Inc. through Morgan Stanley Smith Barney LLC. The approximate sale date is 07 July 2025. Based on the filing, the shares are valued at an aggregate market price of $420,000, representing roughly 0.023 % of the 63,864,504 shares outstanding. The shares were acquired on the same day through a stock-option exercise paid in cash.

The filer also disclosed a prior sale of 15,000 shares on 24 June 2025 that generated $390,000 in gross proceeds.

• No relationship to the issuer was specified in the form, and no adverse information was cited.
• The filing indicates compliance with Rule 144 and possible 10b5-1 planning, but no plan adoption date is provided.

The transaction is small relative to ACMR鈥檚 share count, suggesting limited share-supply impact. However, repeated insider-level sales within a short window may draw investor attention.

Verisk Analytics, Inc. (VRSK) has filed a Form 144 indicating the potential sale of 326 shares of its common stock through Merrill Lynch. The shares were acquired on 07/01/2025 via the vesting of a restricted stock unit award under the company鈥檚 equity compensation plan. The proposed sale date is 07/03/2025 on the NASDAQ exchange. At the most recent market price used in the filing, the aggregate value of the shares equals $98,080.36. With 139,884,077 shares outstanding, the transaction represents approximately 0.00023% of Verisk鈥檚 float, suggesting a de-minimis impact on overall share supply. No other sales were reported for the past three months, and no additional remarks, 10b5-1 plan details, or material non-public information were disclosed in the notice.

Verisk Analytics, Inc. (VRSK) has submitted a Form 144 indicating that insider Nicholas Daffan plans to sell up to 5,419 shares of common stock. Based on the filing鈥檚 stated aggregate market value of $1.63 million, the block represents about 0.004 % of the company鈥檚 139.9 million shares outstanding鈥攁n immaterial percentage in float terms.

The shares, acquired via recent option exercises and the vesting of restricted and performance share units, are slated for sale on or about July 3, 2025 through Merrill Lynch on the NASDAQ exchange. The same seller disposed of an identical 5,419-share block on June 4, 2025, generating $1.72 million in gross proceeds. Form 144 is a notice only; the transaction may or may not ultimately occur.

• No proceeds accrue to Verisk; the sale is by an individual shareholder.
• The filing satisfies Rule 144鈥檚 advance-notice requirement for affiliates selling restricted or control stock.